Betanis, Tradjenta and Onbrez priced and set for launch in Japan
This article was originally published in Scrip
Astellas' first-in-class overactive bladder therapy Betanis (mirabegron) has received a price in Japan and will be included in the national reimbursement tariff on 12 September, clearing the way for its first launch worldwide.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.